ICMJE DISCLOSURE FORM

Date: ___ January 27, 2022____________________________________________________
Your Name: Shizhong Wu___________________________________________________
Manuscript Title: Bromodomain containing 4 transcriptionally activated Deltex E3 ubiquitin ligase 2 contributes to glioma progression and predicts an unfavorable prognosis ____________________________________________
Manuscript number (if known): ATM-22-555_____________________________________

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| Time frame: Since the initial planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | _x_ None |
|   | No time limit for this item.                                                             |                                                                                     |
| Time frame: past 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).                 | _x_ None |
| 3 | Royalties or licenses                                                                     | _x_ None |
| 4 | Consulting fees                                                                         | _X_ None |
|   | Description                                                                 | X | None |
|---|-----------------------------------------------------------------------------|----|------|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus,        | X  | None |
|   | manuscript writing or educational events                                   |    |      |
| 6 | Payment for expert testimony                                               | X  | None |
| 7 | Support for attending meetings and/or travel                               | X  | None |
| 8 | Patents planned, issued or pending                                         | X  | None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board          | X  | None |
| 10| Leadership or fiduciary role in other board, society, committee or advocacy| X  | None |
|   | group, paid or unpaid                                                       |    |      |
| 11| Stock or stock options                                                     | X  | None |
| 12| Receipt of equipment, materials, drugs, medical writing, gifts or other    | X  | None |
|   | services                                                                    |    |      |
| 13| Other financial or non-financial interests                                 | X  | None |

Please summarize the above conflict of interest in the following box:

The author has no conflicts of interest to declare.

Please place an “X” next to the following statement to indicate your agreement:

_X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: ___January 27, 2022_______________________________
Your Name: Shang-Hang Shen______________________________
Manuscript Title: Bromodomain containing 4 transcriptionally activated Deltex E3 ubiquitin ligase 2 contributes to glioma progression and predicts an unfavorable prognosis ____________________________________________
Manuscript number (if known): ATM-22-555______________________________

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
|   | Time frame: Since the initial planning of the work                                              |                                                                                  |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | __x__None                                                                      |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).                      | _x__None                                                                        |
| 3 | Royalties or licenses                                                                         | __x__None                                                                        |
| 4 | Consulting fees                                                                               | __X__None                                                                        |
|   | Time frame: past 36 months                                                                    |                                                                                  |
|   |   |   |
|---|---|---|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ___ X ___ None |
| 6 | Payment for expert testimony | ___ X ___ None |
| 7 | Support for attending meetings and/or travel | ___ X ___ None |
| 8 | Patents planned, issued or pending | ___ X ___ None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | ___ X ___ None |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ___ X ___ None |
| 11 | Stock or stock options | ___ X ___ None |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ___ X ___ None |
| 13 | Other financial or non-financial interests | ___ X ___ None |

Please summarize the above conflict of interest in the following box:

The author has no conflicts of interest to declare.

Please place an “X” next to the following statement to indicate your agreement:

_X__ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: ____ January 27, 2022 ____________________________________________
Your Name: Feng Lu __________________________________________________
Manuscript Title: Bromodomain containing 4 transcriptionally activated Deltex E3 ubiquitin ligase 2 contributes to glioma progression and predicts an unfavorable prognosis _______________________
Manuscript number (if known): ATM-22-555 ______________________________

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
|   | **Time frame: Since the initial planning of the work**                                           |                                                                                  |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | __x__ None                                                                       |
|   | **Time frame: past 36 months**                                                                   |                                                                                  |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).                        | __x__ None                                                                       |
| 3 | Royalties or licenses                                                                           | __x__ None                                                                       |
| 4 | Consulting fees                                                                                 | __X__ None                                                                       |
|   | Description                                                                 | X | None |
|---|------------------------------------------------------------------------------|----|------|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus,         |    | None |
|   | manuscript writing or educational events                                     |    |      |
| 6 | Payment for expert testimony                                                 | _X | None |
| 7 | Support for attending meetings and/or travel                                 | _X | None |
| 8 | Patents planned, issued or pending                                           | _X | None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board            | _X | None |
|10 | Leadership or fiduciary role in other board, society, committee or advocacy  | _X | None |
|   | group, paid or unpaid                                                         |    |      |
|11 | Stock or stock options                                                       | _X | None |
|12 | Receipt of equipment, materials, drugs, medical writing, gifts or other      | _X | None |
|   | services                                                                      |    |      |
|13 | Other financial or non-financial interests                                   | _X | None |

Please summarize the above conflict of interest in the following box:

The author has no conflicts of interest to declare.

Please place an “X” next to the following statement to indicate your agreement:

_X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: ___ January 27, 2022____________________________
Your Name: Pengfeng Zheng
Manuscript Title: Bromodomain containing 4 transcriptionally activated Deltex E3 ubiquitin ligase 2 contributes to glioma progression and predicts an unfavorable prognosis
Manuscript number (if known): ATM-22-555

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | _x__ None |
|   | Time frame: Since the initial planning of the work |  |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | _x__ None |
| 3 | Royalties or licenses | _x__ None |
| 4 | Consulting fees | __ X __ None |

|   | Time frame: past 36 months |
|---|---------------------------|
|   |  |
|   |  |
|   |  |
|   |  |
|   |                                                                                           |   |
|---|--------------------------------------------------------------------------------------------|---|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ___ X _None |
| 6 | Payment for expert testimony                                                               | _ X __None |
| 7 | Support for attending meetings and/or travel                                               | _ X __None |
| 8 | Patents planned, issued or pending                                                          | _ X __None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board                          | ___ X __None |
| 10| Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | _ X ___None |
| 11| Stock or stock options                                                                     | _ X __None |
| 12| Receipt of equipment, materials, drugs, medical writing, gifts or other services            | ___ X __None |
| 13| Other financial or non-financial interests                                                   | ___ X __None |

**Please summarize the above conflict of interest in the following box:**

The author has no conflicts of interest to declare.

**Please place an “X” next to the following statement to indicate your agreement:**

_X__ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: ___ January 27, 2022____________________________________________________
Your Name: ___ Kun Lin____________________________________________________
Manuscript Title: ___ Bromodomain containing 4 transcriptionally activated Deltex E3 ubiquitin ligase 2 contributes to glioma progression and predicts an unfavorable prognosis ______________________
Manuscript number (if known): _______ ATM-22-555_____________________________________

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| Item | Description | Time frame: Since the initial planning of the work | Time frame: past 36 months |
|------|-------------|----------------------------------------------------|---------------------------|
| 1    | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | _x_ None |   |
| 2    | Grants or contracts from any entity (if not indicated in item #1 above). | _x_ None |   |
| 3    | Royalties or licenses | _x_ None |   |
| 4    | Consulting fees | _X_ None |   |
|   |                                                                                           |   |
|---|-------------------------------------------------------------------------------------------|---|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ___ X ___None |
| 6 | Payment for expert testimony                                                             | __ X __None |
| 7 | Support for attending meetings and/or travel                                              | ___ X ___None |
| 8 | Patents planned, issued or pending                                                        | __ X __None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board                        | ___ X ___None |
| 10| Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ___ X ___None |
| 11| Stock or stock options                                                                    | ___ X ___None |
| 12| Receipt of equipment, materials, drugs, medical writing, gifts or other services          | ___ X ___None |
| 13| Other financial or non-financial interests                                                 | ___ X ___None |

Please summarize the above conflict of interest in the following box:

The author has no conflicts of interest to declare.

Please place an “X” next to the following statement to indicate your agreement:

___ X ___ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: ___ January 27, 2022______________________________
Your Name: Jingwei Liao

Manuscript Title: Bromodomain containing 4 transcriptionally activated Deltex E3 ubiquitin ligase 2 contributes to glioma progression and predicts an unfavorable prognosis
Manuscript number (if known): ATM-22-555

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | _x_ None                                                                            |
|   | **No time limit for this item.**                                                               |                                                                                   |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).                      | _x_ None                                                                            |
| 3 | Royalties or licenses                                                                          | _x_ None                                                                            |
| 4 | Consulting fees                                                                                | _X_ None                                                                            |
|   | Question                                                                 | X | None |
|---|-------------------------------------------------------------------------|---|------|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus,    | X | None |
|   | manuscript writing or educational events                                |   |      |
| 6 | Payment for expert testimony                                           | X | None |
| 7 | Support for attending meetings and/or travel                            | X | None |
| 8 | Patents planned, issued or pending                                      | X | None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board       | X | None |
| 10| Leadership or fiduciary role in other board, society, committee or     | X | None |
|   | advocacy group, paid or unpaid                                          |   |      |
| 11| Stock or stock options                                                  | X | None |
| 12| Receipt of equipment, materials, drugs, medical writing, gifts or other | X | None |
|   | services                                                                |   |      |
| 13| Other financial or non-financial interests                               | X | None |

Please summarize the above conflict of interest in the following box:

The author has no conflicts of interest to declare.

Please place an “X” next to the following statement to indicate your agreement:

_X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: ___ January 27, 2022______________________________
Your Name: __ Xiaohang Jiang______________________________
Manuscript Title: ___ Bromodomain containing 4 transcriptionally activated Deltex E3 ubiquitin ligase 2 contributes to glioma progression and predicts an unfavorable prognosis ____________________________
Manuscript number (if known): ______ ATM-22-555_________________________

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
|   | Time frame: Since the initial planning of the work                                                                                     |                                                                                  |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | __x__None                                                                        |                                                                                  |
|   | Time frame: past 36 months                                                                                                              |                                                                                  |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).                                                               | _x__None                                                                         |                                                                                  |
| 3 | Royalties or licenses                                                                                                                  | __x__None                                                                         |                                                                                  |
| 4 | Consulting fees                                                                                                                         | __X__None                                                                         |                                                                                  |
|   | **Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events** | ___ X _None |
|---|-------------------------------------------------------------------------------------------------|-------------|
| 6 | **Payment for expert testimony** | __ X __None |
| 7 | **Support for attending meetings and/or travel** | __ X __None |
| 8 | **Patents planned, issued or pending** | __ X __None |
| 9 | **Participation on a Data Safety Monitoring Board or Advisory Board** | ___ X __None |
| 10 | **Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid** | _ X __None |
| 11 | **Stock or stock options** | __ X __None |
| 12 | **Receipt of equipment, materials, drugs, medical writing, gifts or other services** | ___ X __None |
| 13 | **Other financial or non-financial interests** | ___ X __None |

Please summarize the above conflict of interest in the following box:

The author has no conflicts of interest to declare.

Please place an “X” next to the following statement to indicate your agreement:

__ X __ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: ___ January 27, 2022_____________________________________________________

Your Name: __ Guangming Zeng________________________________________________

Manuscript Title: ____ Bromodomain containing 4 transcriptionally activated Deltex E3 ubiquitin ligase 2 contributes to glioma progression and predicts an unfavorable prognosis ______________________________________

Manuscript number (if known): ______ ATM-22-555_____________________________________

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
|   | Time frame: Since the initial planning of the work                                                  |                                                                                     |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | _X__ None                                                                          |
|   | No time limit for this item.                                                                    |                                                                                     |
|   |                                                                                                  |                                                                                     |
|   |                                                                                                  |                                                                                     |
|   |                                                                                                  |                                                                                     |
|   |                                                                                                  |                                                                                     |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).                        | _X__ None                                                                          |
|   |                                                                                                  |                                                                                     |
| 3 | Royalties or licenses                                                                          | _X__ None                                                                          |
|   |                                                                                                  |                                                                                     |
| 4 | Consulting fees                                                                                 | _X__ None                                                                          |
|   |                                                                                                  |                                                                                     |
|   |                                                                                                  |                                                                                     |
|   |                                                                                                  |                                                                                     |
|   | Description                                                                 | X | None |
|---|------------------------------------------------------------------------------|----|------|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | X | None |
| 6 | Payment for expert testimony                                                 | X | None |
| 7 | Support for attending meetings and/or travel                                  | X | None |
| 8 | Patents planned, issued or pending                                            | X | None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board             | X | None |
| 10| Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | X | None |
| 11| Stock or stock options                                                        | X | None |
| 12| Receipt of equipment, materials, drugs, medical writing, gifts or other services | X | None |
| 13| Other financial or non-financial interests                                    | X | None |

Please summarize the above conflict of interest in the following box:

The author has no conflicts of interest to declare.

Please place an “X” next to the following statement to indicate your agreement:

_X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: ___ January 27, 2022____________________________________________________
Your Name: __ De Wei____________________________________________________
Manuscript Title: ____ Bromodomain containing 4 transcriptionally activated Deltex E3 ubiquitin ligase 2 contributes to glioma progression and predicts an unfavorable prognosis
Manuscript number (if known): ______ ATM-22-555_____________________________________

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| **Time frame: Since the initial planning of the work** | | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  
**No time limit for this item.** | _x__None |

| **Time frame: past 36 months** | | |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | _x__None |
| 3 | Royalties or licenses | _x__None |
| 4 | Consulting fees | _X__None |
|   | Conflict of Interest | Agreement |
|---|---------------------|-----------|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | X None |
| 6 | Payment for expert testimony | None |
| 7 | Support for attending meetings and/or travel | None |
| 8 | Patents planned, issued or pending | None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None |
| 11 | Stock or stock options | None |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None |
| 13 | Other financial or non-financial interests | None |

Please summarize the above conflict of interest in the following box:

The author has no conflicts of interest to declare.

Please place an “X” next to the following statement to indicate your agreement:

_X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.